{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:22:17Z","timestamp":1778412137319,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2022.101031","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T07:30:53Z","timestamp":1668151853000},"page":"101031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Haploidentical bone marrow transplants with post transplant cyclophosphamide on day\u00a0+\u00a03\u00a0+\u00a05: The Genova protocol"],"prefix":"10.1016","volume":"62","author":[{"given":"Anna Maria","family":"Raiola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Angelucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.blre.2022.101031_bb0005","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow ransplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.101031_bb0010","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/210139a0","article-title":"Production of graft-versus-host disease in the rat and its treatment with cytotoxic agents","volume":"210","author":"Santos","year":"1966","journal-title":"Nature."},{"issue":"11","key":"10.1016\/j.blre.2022.101031_bb0015","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.blre.2022.101031_bb0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","article-title":"Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning","volume":"19","author":"Raiola","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2022.101031_bb0025","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.bbmt.2018.01.031","article-title":"A modified post-transplant cyclophosphamide regimen, for unmanipulated haploidentical marrow transplantation, in acute myeloid leukemia: a multicenter study","volume":"24","author":"Chiusolo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2022.101031_bb0030","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41409-019-0594-1","article-title":"Graft versus host disease in unmanipulated haploidentical marrow transplantation with a modified post-transplant cyclophosphamide (PT-CY) regimen: an update on 425 patients","volume":"54","author":"Bacigalupo","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2022.101031_bb0035","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/bloodadvances.2020001729","article-title":"Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis with posttransplantation cyclophosphamide","volume":"4","author":"De Zern","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2022.101031_bb0040","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/cncr.31228","article-title":"Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using post-transplant cyclophosphamide","volume":"124","author":"Ruggeri","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2022.101031_bb0045","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell\u2013replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2022.101031_bb0050","unstructured":"Giammarco S, Raiola AM, Di Grazia C et al. Second haploidentical stem cell transplantation for primary graft failure. Bone Marrow Transplant."},{"key":"10.1016\/j.blre.2022.101031_bb0055","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bbmt.2015.05.001","article-title":"Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation","volume":"21","author":"Ciurea","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2022.101031_bb0060","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in Haploidentical hematopoietic cell transplantation","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2022.101031_bb0065","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2020.06.026","article-title":"Timing of post-transplantation cyclophosphamide administration in haploidentical transplantation: a comparative study on behalf of the acute leukemia working party of the European Society for blood and marrow transplantation","volume":"26","author":"Ruggeri","year":"2020","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22001059?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X22001059?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:31Z","timestamp":1759437091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X22001059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":13,"alternative-id":["S0268960X22001059"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2022.101031","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Haploidentical bone marrow transplants with post transplant cyclophosphamide on day\u00a0+\u00a03\u00a0+\u00a05: The Genova protocol","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2022.101031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101031"}}